Medibios Laboratories Limited IPO

Medibios Laboratories Limited was incorporated in the year 1995 at Mumbai with an object to manufacture and market pharmaceutical products in a domestic and international market. We are located in Mumbai and have a manufacturing unit situated at MIDC, Tarapur Industrial Area, Maharashtra. Our manufacturing facilities are accredited with World Health Organization Good Manufacturing Practice Certification, Food and Drug Administration Philippines, Cosmetic Devices and Drug Authority of Sri Lanka, National Drug Authority Uganda, Food and Drug Administration Myanmar,DPML (Direction De La Pharmacie Du Medicament Et Des Laboratories) Ivory Coast, National Agency for Food and Drug Administration and Control – Nigeria and Food and Drug Administration Ghana. Company products are in dosage forms of Tablets, Capsules and Powders. Our product portfolio includes more than 200 formulations across 20 therapeutic categories which are manufactured at our facilities. Our products are registered with ISP Chile, Uruguay, Suriname, Venezuela, Costa Rica, Cosmetic Devices, and Drug Authority of Sri Lanka, Drug Regulation Services Botswana, Food DA Vietnam, Georgia, Azerbaijan, Hong Kong, etc. We have entered into an agreement with a Sri Lanka based Company for marketing of our brands in Sri Lanka, while we have invested in an Associate Company ―Medvin Pharma Limited‖ in Uganda which is engaged in the wholesale and retail sale of medicines in Uganda and surrounding countries.
We have recently set up a wholly owned subsidiary in Ghana Medibios Laboratories Ghana Private Limited‖ for marketing and distribution of our products there.
Our business is based on three core models
(i) Contract Manufacturing
(ii) Marketing Own Brands and
(iii) Loan License
We majorly carry our business on contract manufacturing for multinational companies, However, recently we have shifted our focus to Direct Manufacturing and Direct Exports to overseas clients, and we propose to expand our business using the same model. In addition, Medibios now as part of its long-term strategy, has started focusing on marketing own brands through dedicated Medibios Marketing Team appointed under its own wholly owned subsidiary or in partnership with importers/marketing agents in respective countries. This model will help Medibios build brands which will provide sustained revenue, growth and improved margins compared to the contract manufacturing and loan license business model.
We currently export our products to over 20 countries which include countries in South East Asia, Africa, and Central and Latin America. We plan to upgrade our manufacturing facility and get it approved by PIC/s Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) member countries, European Union – Good Manufacturing Practices and World Health Organization – Geneva by mid 2019 and increase our basket of Bioequivalent Generic Products for the regulated markets.